-
Something wrong with this record ?
Pharmaceutical pricing and reimbursement in Kyrgyzstan
authors Peter Schneider and Sabine Vogler
- Published
-
Copenhagen : WHO Regional Office for Europe, [2016]
©2016
- Pagination
- x, 69 stran : ilustrace, tabulky
Language English Country Denmark
Knihovny.cz ISBN
978-92-8-905219-1
plný text volně přístupný
Knihovny.cz E-resources
- MeSH
- Financing, Personal MeSH
- Costs and Cost Analysis MeSH
- Drug Costs MeSH
- Outpatients MeSH
- Fees, Pharmaceutical MeSH
- Insurance, Health, Reimbursement MeSH
- Health Expenditures MeSH
- Geographicals
- Kyrgyzstan MeSH
- Conspectus
- Veřejné zdraví a hygiena
- NML Fields
- veřejné zdravotnictví
- NML Publication type
- publikace WHO
This report explores the causes of high out-of-pocket (OOP) payments for outpatient medicines in Kyrgyzstan and develops policy recommendations to reduce them. The analysis consisted of a review of current reimbursement mechanisms and an assessment of their ability to protect the Kyrgyz population from high OOP payments. The analysis showed that Kyrgyz patients have been confronted with increasing co-payments for reimbursed medicines in the outpatient sector. Compared to the 2013 figures, copayments for medicines prescribed and dispensed under the reimbursed drug package increased by 20% in 2015. A contributing factor for this increase is the absence of price regulation for medicines. Another reason for observed price increases may be related to currency devaluation. Based on the findings of the analysis, this report proposes several policy options to address high OOP payments, including: introduction of price regulation including control of retail margins, review of reimbursement processes, strengthening of information systems for monitoring and evaluation, and capacity building of the stakeholders.
Obsahuje bibliografické odkazy
| Owner | Details | Services |
|---|---|---|
| NLK | NLK Shelf no. online [0] | see E-resources |
- 000
- 00000nam a2200000 i 4500
- 001
- MED00192278
- 003
- CZ-PrNML
- 005
- 20170810101115.0
- 008
- 170801s2016 dk d eo 000 0|eng||
- 009
- eBK
- 020 __
- $a 978-92-8-905219-1
- 040 __
- $a ABA008 $b cze $d ABA008 $e rda
- 041 0_
- $a eng
- 044 __
- $a dk
- 072 _7
- $a 614 $x Veřejné zdraví a hygiena $2 Konspekt $9 14 $7 sk136314
- 100 1_
- $a Schneider, Peter $7 xx0215647 $4 aut
- 245 10
- $a Pharmaceutical pricing and reimbursement in Kyrgyzstan / $c authors Peter Schneider and Sabine Vogler
- 264 _1
- $a Copenhagen : $b WHO Regional Office for Europe, $c [2016]
- 264 _4
- $c ©2016
- 300 __
- $a x, 69 stran : $b ilustrace, tabulky
- 336 __
- $a text $b txt $2 rdacontent
- 337 __
- $a počítač $b c $2 rdamedia
- 338 __
- $a online zdroj $b cr $2 rdacarrier
- 347 __
- $a textový soubor $b PDF $2 rda
- 504 __
- $a Obsahuje bibliografické odkazy
- 520 9_
- $a This report explores the causes of high out-of-pocket (OOP) payments for outpatient medicines in Kyrgyzstan and develops policy recommendations to reduce them. The analysis consisted of a review of current reimbursement mechanisms and an assessment of their ability to protect the Kyrgyz population from high OOP payments. The analysis showed that Kyrgyz patients have been confronted with increasing co-payments for reimbursed medicines in the outpatient sector. Compared to the 2013 figures, copayments for medicines prescribed and dispensed under the reimbursed drug package increased by 20% in 2015. A contributing factor for this increase is the absence of price regulation for medicines. Another reason for observed price increases may be related to currency devaluation. Based on the findings of the analysis, this report proposes several policy options to address high OOP payments, including: introduction of price regulation including control of retail margins, review of reimbursement processes, strengthening of information systems for monitoring and evaluation, and capacity building of the stakeholders.
- 650 07
- $a poplatky farmaceutické $7 D005252 $2 czmesh
- 650 07
- $a financování osobní $7 D005382 $2 czmesh
- 650 07
- $a pacienti ambulantní $7 D010045 $2 czmesh
- 650 07
- $a náklady a analýza nákladů $7 D003365 $2 czmesh
- 650 07
- $a úhrada zdravotního pojištění $7 D007349 $2 czmesh
- 650 07
- $a náklady na léky $7 D016527 $2 czmesh
- 650 07
- $a výdaje na zdravotnictví $7 D005102 $2 czmesh
- 650 07
- $a veřejné zdravotnictví $7 nlk20040148357 $2 mednas
- 651 _7
- $a Kyrgyzstán $7 D007707 $2 czmesh
- 655 _4
- $a publikace WHO $7 nlk20040156070
- 700 1_
- $a Vogler, Sabine $7 xx0126854 $4 aut
- 856 41
- $u http://www.euro.who.int/__data/assets/pdf_file/0005/325823/Pharmaceutical-pricing-reimbursement-reform-Kyrgyzstan.pdf?ua=1 $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $y 0
- 990 __
- $a 20170801160337 $b ABA008
- 991 __
- $a 20170810101637 $b ABA008
- 999 __
- $a ok $b medvik21 $g 1241187 $s 206281
- BAS __
- $a 30 $a 49
- LZP __
- $b 2017online